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S U M M A R Y
Objective: In order to deﬁne the current characteristics of infective endocarditis (IE) in Turkey, we
evaluated IE cases over a 14-year period in a tertiary referral hospital.
Methods: All adult patients who were hospitalized in our hospital with a diagnosis of IE between
2000 and 2013 were included in the study. Modiﬁed Duke criteria were used for diagnosis. The Chi-
square test, Student’s t-test, Mann–Whitney U-test, Cox and logistic regression analysis were used for
the statistical analysis.
Results: There were 325 IE cases during the study period. The mean age of the patients was 47 years.
Causative microorganisms were identiﬁed in 253 patients (77.8%) and included staphylococci (36%),
streptococci (19%), enterococci (7%), and Brucella spp (5%). A streptococcal aetiology was associated with
younger age (<40 years) (p = 0.001), underlying chronic rheumatic heart disease (CRHD) (odds ratio (OR)
3.89) or a congenital heart defect (OR 4.04), community acquisition (OR 17.93), and native valve (OR
3.68). A staphylococcal aetiology was associated with healthcare acquisition (OR 2.26) or pacemaker
lead-associated endocarditis (OR 6.63) and an admission creatinine level of >1.2 mg/dl (OR 2.15). Older
age (>50 year) (OR 3.93), patients with perivalvular abscess (OR 9.18), being on dialysis (OR 6.22), and
late prosthetic valve endocarditis (OR 3.15) were independent risk factors for enterococcal IE. Independent
risk factors for mortality in IE cases were the following: being on dialysis (hazard ratio (HR) 4.13), presence
of coronary artery heart disease (HR 2.09), central nervous system emboli (HR 2.33), and congestive heart
failure (HR 2.15). Higher haemoglobin (HR 0.87) and platelet (HR 0.996) levels and surgical interventions
for IE (HR 0. 33) were found to be protective factors against mortality.
Conclusions: In Turkey, IE occurs in relatively young patients and Brucella spp should always be taken
into consideration as a cause of this infection. We should ﬁrst consider streptococci as the causative
agents of IE in young patients, those with CRHD or congenital heart valve disease, and cases of community-
acquired IE. Staphylococci should be considered ﬁrst in the case of pacemaker lead IE, when there are high
levels of creatinine, and in cases of healthcare-associated IE. Enterococci could be the most probable
causative agent of IE particularly in patients aged >50 years, those on dialysis, those with late prosthetic
valve IE, and those with a perivalvular abscess. The early diagnosis and treatment of IE before complications
develop is crucial because the mortality rate is high among cases with serious complications. The
prevention of bacteraemia with the measures available among chronic haemodialysis patients should be a
priority because of the higher mortality rate of subsequent IE among this group of patients.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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Despite its rare occurrence, infective endocarditis (IE) is an
important disease because of the difﬁculties in diagnosis and
treatment and the high morbidity and mortality rates. The proﬁle
of IE differs between developed and developing countries. In
industrialized countries, a decrease in rheumatic heart disease and
increase in degenerative heart disease has led to an increase in
patient age, frequency of comorbidities, and incidence of
Staphylococcus aureus, which is acquired mainly from healthcare,
and IE still has a high mortality.1,2 In developing countries, patient
age, place of acquisition of the infection, and causative micro-
organisms may be different because of the ongoing higher rate of
chronic rheumatic heart disease (CRHD).
The identiﬁcation of causative microorganisms is crucial in
the management of IE cases. Although the rate of identiﬁcation of
the causative microorganism is reported to be very high in the
developed world, it is lower in developing countries.3–7 Knowledge
of the risk factors for speciﬁc microorganisms could be beneﬁcial in
those cases of IE with an undetermined aetiology. Because IE is a
rare disease, case numbers are generally low in studies on IE.8–12 In
this study, we evaluated the aetiology and clinical and laboratory
ﬁndings of IE cases over a 14-year period at a tertiary referral
hospital; we also determined risk factors for Streptococcus spp,
Staphylococcus spp, and Enterococcus spp IE. Further, we deﬁned the
risk factors for mortality in IE in the population of a tertiary
hospital in Turkey.
2. Materials and methods
All adult patients (age >14 years) who were hospitalized in
Siyami Ersek Cardiovascular Surgery Hospital with a diagnosis of IE
between January 2000 and October 2013 were included in the
study. Clinical and laboratory ﬁndings of patients were recorded
prospectively in the ﬁrst 5 years and retrospectively thereafter. The
following variables were recorded for each patient: age, sex,
underlying cardiac predisposition, intravenous drug use (IVDU),
comorbid conditions before IE (diabetes mellitus, chronic renal
failure, congestive heart failure (CHF), hypertension, chronic
obstructive lung disease, being on chronic haemodialysis), admis-
sion complaints, physical investigation ﬁndings, healthcare or
community acquisition, laboratory values (blood sugar, blood urea
nitrogen, serum creatinine, C-reactive protein (CRP), alanine
aminotransferase (ALT), rheumatoid factor, haemoglobin level,
platelet and white blood cell (WBC) counts, erythrocyte sedimen-
tation rate (ESR) at the time of diagnosis), blood culture results,
echocardiography ﬁndings, results of the Wright agglutination
test, antimicrobial treatments, surgical interventions, complica-
tions, and mortality.
Modiﬁed Duke criteria were used for the diagnosis of IE.1 All
patients who were discharged from the hospital within 6 months
before the onset of symptoms were accepted as having hospital-
acquired IE.13
The identiﬁcation of Staphylococcus spp was performed using
standard methods. Methicillin resistance in staphylococci was
determined using a disk diffusion test with a 30-mg cefoxitin disk.
Identiﬁcation of streptococci and enterococci, Gram-negative
enteric rods, Gram-negative non-fermentative rods, and Candida
spp were done with API Strep, API 20E, API NE, and API CAUX
(bioMe´rieux, France), respectively, along with standard methods.
Brucella spp were identiﬁed using standard methods (biotyping,
sensitivity to dyes, penicillin and streptomycin susceptibility, H2S
production, CO2 requirement, phage sensitivity) and species-
speciﬁc antisera. HACEK microorganisms, Granulicatella elegans,
Bacillus licheniformis, and Kytococcus schroeteri, were identiﬁed
using 16S ribosomal RNA analysis. Bartonella henselae DNA wasdetermined using a nested PCR. Minimal inhibitory concentrations
of penicillin G, gentamicin, ceftriaxone, oxacillin, and vancomycin
were determined using the Etest method. Susceptibilities to other
antimicrobial agents were determined with the Clinical and
Laboratory Standards Institute (CLSI) disk diffusion method.
Mortality was deﬁned as in-hospital death.
Statistical analyses were done using SPSS for Windows version
16.0 (SPSS Inc., Chicago, IL, USA). The Chi-square test and Student’s t-
test were used for the univariate analysis of categorical and
continuous variables of patient characteristics, respectively. The
distribution of continuous variables was investigated with visual
(histograms, probability plots) and analytical (Kolmogorov–Smir-
nov/Shapiro–Wilk tests) methods; variables with a non-normal
distribution were compared using the Mann–Whitney U-test.
Independent risk factors for IE caused by Streptococcus spp,
Staphylococcus spp, and Enterococcus spp were determined using
multiple logistic regression analysis. Cox regression analysis with
backward selection was used to determine independent predictors
of mortality. Variables found to be signiﬁcant (p < 0.05) in the
univariate analysis were included in the logistic and Cox regression
analyses. Among correlated factors with similar effects on survival,
only those with clinical signiﬁcance were included. The proportional
hazards assumption and model ﬁt were assessed by means of
residual analysis (Schoenfeld and Martingale).
3. Results
A total of 325 adult IE cases occurred between January 2000 and
October 2013. One hundred two of 325 patients were recorded
prospectively, while 223 were recorded retrospectively at the end
of 2013.
Baseline characteristics, predisposing conditions, and clinical
and laboratory ﬁndings on admission for the 325 endocarditis
cases are shown in Tables 1 and 2. According to the modiﬁed Duke
criteria, 280 (86.2%) patients were classiﬁed as having deﬁnite IE
and 45 (13.8%) as having probable IE. The mean age of patients was
47 years (range 14–90 years) (Table 2). The numbers of patients
aged younger than 40, 50, and 65 years were 119 (36.6%), 168
(51.6%), and 277 (85.2%), respectively. Mean patient age did not
differ across the years (p = 0.967). The mean length of hospital stay
was 36.59  22.79 days (range 2–215 days).
3.1. Causative agents of infective endocarditis cases
The causative microorganism was identiﬁed in 252 patients, by
positive blood culture (n = 228), positive heart valve culture
(n = 13), both blood and heart valve culture (n = 6), positive Wright
agglutination test (n = 4), and blood PCR positivity (n = 1). The
causative microorganisms are shown in Table 3. Staphylococci
were the most frequently isolated microorganisms (36.1%) when
all of the IE cases were taken into consideration. The distribution of
causative agents is shown by age range in Figure 1. Streptococci
were signiﬁcantly more prevalent in patients aged <40 years
(p = 0.001), while enterococci were signiﬁcantly more prevalent in
patients aged >50 years (p = 0.018). The incidence of S. aureus,
coagulase-negative staphylococci (CoNS), and Brucella spp were
not different among IE cases (p = 0.319, 0.131, and 0.436,
respectively).
Streptococci were the leading cause of IE in patients with a
native valve (52/166, 31%) (p = 0.000), while staphylococci were
the leading cause in patients with an intracardiac prosthesis (58/
159, 36%). CoNS, methicillin-resistant S. aureus (MRSA), Gram-
negative rods, Enterococcus spp, and Candida spp were isolated
more frequently from patients with an intracardiac device than
patients with a native valve (p = 0.011, 0.038, 0.001, 0.014, and
0.022, respectively).
Table 1
Predisposing conditions, complaints, and clinical and laboratory ﬁndings of patients with infective endocarditis
Feature n (%) Feature n (%)
Predisposing conditions Complaints
Chronic rheumatic heart disease 110 (33.9) Fever 276 (84.9)
Prosthetic valve 141 (43.5) Dyspnoea 131 (40.5)
Pace/ICD* 18 (5.6) Fatigue 118 (36.4)
Previous infective endocarditis 18 (5.6) Anorexia and weight loss 33 (10.2)
Bicuspid aortic valve 18 (5.6) Arthralgia 19 (5.9)
Other congenital heart defects 26 (8.0) Headache and change in consciousness 15 (4.6)
Structural heart valve disease 12 (3.3) Physical investigation and laboratory ﬁndings
Degenerative heart valve disease 19 (5.9) Fever 307 (94.4)
Intravenous drug user 3 (0.9) New murmur 145 (44.8)
Other features Skin rashes 8 (2.5)
Left-sided endocarditis 284 (87.3) Roth spot 5 (1.5)
Aortic valve 124 (38.2) Splenomegaly 55 (16.9)
Mitral valve 124 (38.2) Peripheral arterial emboli 17 (5.2)
Aortic and mitral valve 36 (11.0) Central nervous system emboli 52 (16.6)
Right-sided endocarditis 41 (12.7) Pulmonary emboli 8 (2.5)
Tricuspid valve 21 (6.5) Splenic abscess 15 (4.6)
Pulmonary valve 2 (0.6) Congestive heart failure 104 (32.1)
Place of infection acquisition Vegetation on echocardiography 253 (78.1)
Community-acquired 250 (76.9) Abscess on echocardiography 48 (14.8)
Healthcare-associated 75 (23.1) Haematuria 121 (38.6%)
Nosocomial 33 (10.2) Elevated rheumatoid factor 28 (8.9%)
Non-nosocomial 42 (12.9) Elevated C-reactive protein level
Elevated erythrocyte sedimentation rate
295 (91)
276 (85)
* ICD, implantable cardioverter deﬁbrillator.
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from community-acquired endocarditis (p < 0.000 and 0.173,
respectively), while S. aureus, MRSA, Gram-negatives, and Candida
spp were more frequently associated with healthcare-acquired IE
cases (p = 0.008, 0.001, 0.000, and 0.044, respectively).
Independent risk factors for staphylococcal, enterococcal, and
streptococcal IE are shown in Table 4.
One patient with blood culture-negative IE was positive for B.
henselae DNA by PCR.
3.2. Antimicrobial susceptibility of causative agents and antimicrobial
treatments
All of the streptococci were sensitive to penicillin. All of the
enterococci were sensitive to penicillin, gentamicin, and vanco-
mycin, and none of the enterococci showed high-level resistance to
gentamicin. The rate of methicillin resistance was 32% (36/117)
among Staphylococcus strains isolated from blood cultures of
endocarditis cases. The rate of methicillin resistance was 9% (6/65)
for S. aureus strains and 60% (31/52) for CoNS strains. No
methicillin resistance was seen among S. aureus strains isolated
from community-acquired IE, but the rate of methicillin resistance
was 58% (21/36) among CoNS strains isolated from community-
acquired IE. In healthcare-associated IE cases, the rate of
methicillin resistance was 25% (6/24) for S. aureus strains and
63% (10/16) for CoNS strains. The methicillin resistance rate among
S. aureus strains isolated from healthcare-associated IE cases
decreased signiﬁcantly from 45% to 8% (p = 0.048) after the control
of MRSA infections began in 2006.
Ampicillin–sulbactam plus gentamicin was the most frequently
used antimicrobial combination for the treatment of IE
(63 patients), followed by penicillin or ampicillin plus gentamicin
(56 patients), cefazolin plus gentamicin (59 patients), vancomycin
plus gentamicin (59), ceftriaxone plus gentamicin (10 patients),
and daptomycin plus gentamicin (4 patients).
3.3. Univariate analysis of mortality risk factors (Table 2)
Eighty-six of 325 patients died (27.8%) during their hospital
stay. The rate of mortality did not differ over the years (p > 0.05). Inthe univariate analysis, risk factors that increased mortality in
cases of IE were older age, chronic renal failure, coronary artery
disease, diabetes mellitus, being on dialysis, healthcare-associated
IE, early prosthetic valve IE, central nervous system (CNS) or
peripheral arterial emboli, perivalvular abscess, CHF due to IE,
higher WBC count, lower blood thrombocyte count, lower
haemoglobin level, higher levels of serum CRP, creatinine, and
fasting sugar, higher ESR rate, and S. aureus aetiology (p < 0.05).
Decreased mortality in cases of IE was associated with Streptococ-
cus spp aetiology and surgical intervention for the treatment of IE
(p < 0.05).
3.4. Multivariate analysis of mortality risk factors (Table 2)
In the multivariate analysis, independent risk factors for
mortality in cases of IE were found to be the following: being
on dialysis (hazard ratio (HR) 4.13), the presence of coronary artery
heart disease (HR 2.09), CNS emboli (HR 2.33), and CHF (HR 2.15).
Higher haemoglobin (HR 0.87) and platelet (HR 0.996) levels and
surgical intervention for IE (HR 0. 25) were found to be protective
factors against mortality.
4. Discussion
This study is the largest case series of patients with IE from
Turkey to date. Recent studies from the developed world have
reported the age of patients with IE to be >60 years.2,14 Although
the median age of patients was reported to be 36 years in the
former largest study of IE from Turkey,8 recent studies of IE in
Turkey have found it to be between 45 and 51 years.9–12 Our
ﬁnding of a mean age of 47 years is higher than that reported in the
study from the 1990s and similar to those reported in the recent
studies, but is still lower than the average mean age of patients in
the developed world.1 The major factor contributing to the
younger age of patients with IE could be the higher rate of CRHD
in Turkey. A recent study investigated the causes of heart valve
disease in 1300 cases and concluded that CRHD was the leading
cause of heart valve disease – it constituted 46% of the cases in
Turkey.15 Although the rate of CRHD in Turkey among IE cases
decreased from 64%8 in the 1990s to 18–36% in the 2000s,9–11 it is
Table 2
Baseline characteristics, predisposing conditions, and clinical and laboratory ﬁndings of infective endocarditis patients who died and those who surviveda
Features Total cohort
(N = 325b)
Patients who
died
(n = 234)
Patients who
survived
(n = 87)
Statistical analysis
Univariate
analysis
p-Value
Multivariate analysis
p-Value HR 95% CI
Age, years 46.94  17.11 44.54  17.40 54.04  14.37 <0.001
Sex, male 187 134 53 0.582
Left-sided IE 284 202 78 0.420
Aortic valve endocarditis 156 108 48 0.160
History of previous endocarditis 18 12 6 0.541
Prosthetic valve endocarditis 141
Early prosthetic valve endocarditis 52 25 27 <0.001
Late prosthetic valve endocarditis 89 62 26 0.559
Chronic renal failure 19 9 10 0.010
Coronary heart disease 49 27 22 0.002 0.012 2.09 1.17–3.73
Hypertension 46 34 12 0.864
Diabetes mellitus 31 16 15 0.005
Congestive heart failure before
endocarditis
20 13 7 0.412
Chronic obstructive lung disease 4 4 0 0.220
Chronic haemodialysis 11 3 8 0.001 0.001 4.13 1.83–9.30
Healthcare-associated endocarditis 75 45 30 0.005
Central nervous system emboli 52 23 29 <0.001 0.002 2.33 1.35–4.03
Peripheral arterial emboli 25 14 11 0.049
Splenic abscess 15 8 7 0.082
Paravalvular abscess 48 29 19 0.036
Congestive heart failure 102 55 47 <0.001 0.003 2.15 1.29–3.56
Blood leukocyte count, 109/l 12.02  6.13 10.98  4.67 14.75  8.42 <0.001
Blood thrombocyte count, 109/l 244.950  111.51 261.920  113.73 198.810  91 <0.001 0.09 0.996 0.994–0.998
Blood haemoglobin level, g/dl 10.57  2.04 10.81  2.15 9.92  1.53 <0.001 0.047 0.87 0.76–0.99
Serum CRP level, mg/l 79.53  68.93 71.32  61.69 101.05  81.53 0.002
Serum creatinine level, mg/dl 1.33  1.38 1.07  0.78 1.83  0.21 <0.001
Serum blood sugar level, mg/dl 118.70  46.43 113.70  40.73 131.99  57.24 0.011
Serum ALT level, U/l 43.94  91.50 38.36  77.15 59.04  120.92 0.096
ESR, mm/h 63.98  31.01 61.23  30.10 71.24  32.41 0.009
Vegetation area, cm2 1.35  1.41 1.23  1.17 1.45  1.65 0.346
Staphylococcus aureus IE 65 38 25 0.013
Enterococcus spp IE 21 12 9 0.095
Viridans Streptococcus IE 63 55 8 0.004
Cardiac surgery for IE 168 139 29 <0.001 <0.001 0.33 0.19–0.56
Total length of hospital stay, days 36.59  22.79 38.60  17.29 31.65  33.32 <0.001
HR, hazard ratio; CI, conﬁdence interval; IE, infective endocarditis; CRP, C-reactive protein; ALT, alanine aminotransferase; ESR, erythrocyte sedimentation rate; SD, standard
deviation.
a Results are given as the mean  SD, or as the number or patients.
b Four patients were referred to the other hospitals because of serious complications and removed from the analysis.
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industrialized countries.14 Since the reporting system is not
adequate, it is impossible for us to estimate an accurate incidence
of acute rheumatic fever (ARF) in Turkey. Available evidence
suggests that the incidence of ARF has also been decreasing in
Turkey, but it remains higher than that in the developed world. The
incidence of ARF is reported to be lower than 10 per 100 000 people
in the developed world,16 whereas it is reported to be 20 per
100 000 people in Turkey.17 These ﬁndings suggest that a
comprehensive and sustainable surveillance system for ARF and
CRHD should be established to prevent the disease in Turkey.
Other predisposing conditions for IE, such as the presence of
intracardiac devices or prosthetic valves, were the same as
identiﬁed in other studies. However, the incidence of IVDU among
the cases of IE (0.9%) was lower than rates reported from the
developed world (10%).1
In the present study, the four most frequent causative micro-
organisms were staphylococci, streptococci, enterococci, and
Brucella spp. Recent studies from the developed world1 have also
reported staphylococci to be the most frequently isolated micro-
organisms; these have been shown to be the causative agents of 29%,
78%, 44%, 35% and 36% of native valve, pacemaker lead, early
prosthetic valve, late prosthetic valve and all of IE cases, respectivelyin our study. However, the causative microorganisms of IE differ
from country to country, depending on the underlying predisposing
conditions and place of acquisition of the infection. Streptococci
were the leading cause of endocarditis in patients with a native valve
endocarditis in the present study. This situation may also be related
to the greater presence of patients of younger age with CRHD.
Comorbid conditions are low in these patients and they do not need
frequent hospitalization; as a result they have a lower risk of
healthcare-associated infection such as staphylococcal infection.
In the present study, CoNS, MRSA, Gram-negative rods,
Enterococcus spp, and Candida spp were more frequent in patients
with intracardiac prosthetic devices or valves than in patients with
no prosthesis. Staphylococci and Candida spp were also found more
frequently in patients with an intracardiac device or valve in the
International Collaboration on Endocarditis (ICE) cohort.1
Causative microorganisms were also different among communi-
ty- and healthcare-associated IE in our study: streptococci and
Brucella spp were more frequent in patients with community-
acquired IE and S. aureus, MRSA, Gram-negative rods, and Candida spp
were more frequently isolated in patients with healthcare-associat-
ed IE. S. aureus, MRSA, and Candida spp were also isolated more
frequently from patients with healthcare-associated IE in the study
of Lomas et al.18
Table 3
Causative microorganisms of 325 cases of infective endocarditis
Causative microorganisms Native valve Intracardiac device Total, n (%)
Pacemaker/ ICD*, n Early prosthetic
valve, n
Late prosthetic
valve, n
Deﬁned causative agent 122 15 47 69 253 (77.8)
Staphylococcus spp 49 14 23 31 117 (36.1)
Staphylococcus aureus 31 10 10 14 65 (20.1)
MRSA 1 0 5 0 6 (1.9)
MSSA 30 10 5 14 59 (17.3)
CoNS 18 4 13 17 52 (16.0)
Methicillin-resistant CoNS 10 1 11 9 31 (9.6)
Methicillin-sensitive CoNS 8 3 2 8 21 (6.5)
Streptococcus spp 52 0 2 9 63 (19.4)
Viridans Streptococcus 44 0 2 9 55 (17.0)
Streptococcus bovis 4 0 0 0 4 (1.2)
Nutritionally variant streptococci 4 0 0 0 4 (1.2)
Abiotrophia defectiva 3 0 0 0 3 (0.9)
Granulicatella elegans 1 0 0 0 1 (0.3)
Enterococcus spp 11 0 0 11 22 (6.8)
Enterococcus faecalis 10 0 0 9 19 (5.9)
Enterococcus faecium 1 0 0 2 3 (0.9)
Brucella melitensis 5 1 0 9 15 (4.6)
Non-fermentative Gram-negative rods 2 0 12 2 16 (4.6)
Pseudomonas aeruginosa 1 0 6 1 7 (2.2)
Stenotrophomonas maltophilia 0 0 5 1 6 (1.8)
Acinetobacter baumannii 0 0 1 0 2 (0.6)
Acinetobacter lwofﬁi 1 0 0 0 1 (0.3)
Candida spp 1 0 6 1 8 (2.4)
Candida albicans 0 0 5 0 5 (1.5)
Candida parapsilosis 1 0 1 0 2 (0.6)
Other non-albicans Candida spp 0 0 0 1 1 (0.3)
Enterobacteriaceae 0 0 4 2 6 (1.8)
Escherichia coli 0 0 1 1 2 (0.6)
Enterobacter cloacae 0 0 1 0 1 (0.3)
Klebsiella pneumoniae 0 0 1 1 2 (0.6)
Serratia marcescens 0 0 1 0 1 (0.3)
HACEK 1 0 0 2 3 (0.9)
Eikenella corrodens 1 0 0 0 1 (0.3)
Actinobacillus actinomycetemcomitans 0 0 0 2 2 (0.6)
Kytococcus schroeteri 0 0 0 1 1 (0.3)
Bartonella henselae 0 0 0 1 1 (0.3)
Bacillus licheniformis 1 0 0 0 1 (0.3)
Undeﬁned causative agents 44 3 5 20 72 (22.2)
Total 166 18 52 89 325 (100)
* ICD, implantable cardioverter deﬁbrillator; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive Staphylococcus aureus; CoNS, coagulase-negative
staphylococci;
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ranges in our study. Streptococci were more frequent among
patients aged <40 years and enterococci were more frequent
among patients aged >50 years; this is in accordance with the
current literature.19Brucella spp.
Figure 1. Distribution of the most frequent ﬁve causative It is not always possible to identify fastidious bacteria that
cause IE with traditional methods. Molecular methods are
particularly useful to show the presence of fastidious bacteria
and to identify slow-growing bacteria cultured in blood.20 We
identiﬁed HACEK microorganisms, K. schroeteri, and B. licheniformisagents of infective endocarditis according to decades.
Table 4
Demographic and clinical features of patients with infective endocarditis caused by Streptococcus spp, Staphylococcus spp, and Enterococcus spp
Variablesa Streptococcus spp IE Staphylococcus spp IE Enterococcus spp IE
Multivariate analysis Multivariate analysis Multivariate analysis
Neg
n=262
Pos
n=63
Univ.
p-value
p-Value OR 95% CI Neg
n=208
Pos
n=117
Univ.
p-value
p-Value OR 95% CI Neg
n=303
Pos
n=22
Univ.
p-value
p-Value OR 95% CI
Age, years 4817 4015 0.001 4517 4916 0.035 4617 5614 0.001
>40 years 178 28 0.001 124 82 0.060 188 28 0.063
>50 years 141 16 0.018 0.029 3.93 1.15–13.40
Sex, male 159 32 0.152 115 76 0.089 176 15 0.383
Chronic rheumatic
heart disease
79 31 0.04 0.001 3.89 1.45–10.41 80 30 0.019 101 9 0.489
Chronic renal failure 19 0 0.028 12 7 0.937 14 5 0.000
CHD 44 5 0.078 30 19 0.660 40 9 0.000
Hypertension 41 5 0.092 27 19 0.304 40 6 0.106
Diabetes mellitus 28 3 0.151 18 13 0.469 26 5 0.046
CHF before
endocarditis
17 3 0.609 10 10 0.178 19 1 0.745
History of previous IE 16 2 0.361 13 5 0.455 18 0 0.239
At least one
comorbidity
116 20 0.037 84 52 0.237 120 16 0.007
Chronic haemodialysis 11 0 0.098 8 3 0.540 7 4 0.004 0.049 6.22 1.007–38.43
Healthcare-associated
endocarditis
75 1 0.000 36 40 0.001 0.006 2.26 1.25–4.06 70 6 0.655
Community- acquired
infection
187 62 0.003 0.005 17.93 2.34–137.09
Presence of any
congenital heart
defect
25 16 0.001 0.004 4.04 1.78–9.11 30 11 0.191 41 0 0.065
Presence of intracardiac
device
147 11 0.000 90 68 0.010 147 11 0.893
Native valve (no
intracardiac device)
115 52 0.000 0.003 3.68 1.57–8.62
Presence of prosthetic
valve
130 11 0.000 87 54 0.450 130 11 0.517
Early prosthetic valve
endocarditis
50 2 0.002 29 23 0.177 52 0 0.032
Late prosthetic valve
endocarditis
80 9 0.009 58 31 0.778 78 11 0.014 0.034 3.15 1.08–9.13
Pace-maker lead IE 18 0 0.032 4 14 0.000 0.002 6.63 1.99–22.05 18 0 0.239
Left-sided endocarditis 226 58 0.213 189 95 0.012 163 21 0.238
CNS emboli 48 6 0.092 32 22 0.427 49 5 0.425
Peripheral arterial
emboli
20 6 0.620 17 9 0.878 24 2 0.845
Splenic abscess 12 3 0.951 10 5 0.826 14 1 0.937
Paravalvular abscess 41 7 0.362 35 13 0.163 40 8 0.003 0.000 9.18 2.90–29.04
CHF 85 19 0.727 59 45 0.061 92 12 0.019
Blood leukocyte
count, 109/l
126 106 0.013 116 136 0.002 116 137 0.149
Blood thrombocyte
count, 109/l
245117 24282 0.665 247106 239120 0.533 244111 250107 0.826
Blood haemoglobin
level, gr/dl
10.581.96 10.542.35 0.539 10.502.15 10.691.84 0.543 10.62.08 10.21.39 0.478
Serum CRP level, mg/l 8171 7255 0.844 7760 8281 0.680 7869 8869 0.485
Serum creatinine
level, mg/dl
1.441.51 0.86 0.30 0.001 1.261.31 1.471.49 <0.001 1.251.26 2.412.31 0.023
Serum creatinine
level >1.2 mg/dl
74 9 0.014 42 41 0.002 0.008 2.15 1.22–3.78 76 7 0.404
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S. S¸ ims¸ ek-Yavuz et al. / International Journal of Infectious Diseases 30 (2015) 106–114112using 16S RNA analysis; these were cultured from either blood or
heart valves of patients with IE and could not be identiﬁed with
traditional methods. In contrast to other studies, Brucella spp was
deﬁned as the fourth most frequent cause of IE in our study. In a
study from Algeria, where brucellosis is also endemic like Turkey,
Brucella spp was found to be the causative agent in 1.6% of 62 IE
cases.21 These ﬁndings suggest that causative microorganisms may
be different among countries. Knowledge of the local epidemiology
is required and Brucella spp should be considered as a causative
agent in cases of IE in Turkey. The Wright agglutination test should
be included in the primary serologic testing of IE cases in Turkey.
The rate of determination of causative microorganisms in cases
of IE also differs between countries, probably due to the availability
of advanced technologies. Causative microorganisms are deter-
mined in more than 90% of cases of IE in developed countries,1,22
but only 41–67% of cases of IE in developing countries.3–7 A median
of 68% (range 50–84%) of the causes of IE have been identiﬁed in
studies from Turkey8–12 and we determined the cause in 78% of IE
cases. It would be useful to know the risk factors for certain types of
causative microorganism in the case of an undeﬁned aetiology
among IE cases. The most important features that were found to be
useful in estimating the causative agent in cases of IE in our study
were patient age, predisposing condition (CRHD, congenital heart
disease, presence of intracardiac devices), and whether the
infection was acquired from the community or healthcare
environment. Community-acquired IE, CRHD or a congenital heart
defect as the underlying condition, and the presence of a native
valve were found to be independent risk factors for streptococcal
IE. Healthcare- or pacemaker lead-associated IE and a higher
admission creatinine level in patients (>1.2 mg/dl) were found to
be independent risk factors for staphylococcal IE. In a study of
558 patients with S. aureus-related IE from the ICE cohort, these
patients were also found to be signiﬁcantly more likely to have
healthcare-associated IE than patients with non-S. aureus-related
IE.23 Acute renal failure and higher creatinine levels in patients
with IE caused by S. aureus is a well deﬁned situation.24 In our
study, independent risk factors for enterococcal IE were older age
(>50 years), patients with perivalvular abscess, being on dialysis,
and late prosthetic valve endocarditis. In recent studies, the most
distinctive reported features of enterococcal IE are that it more
frequently affects the elderly and patients with a prosthetic
valve,19,25 and more often causes the development of intracardiac
abscesses in patients with a prosthetic valve.25 In a study of IE in
40 haemodialysis patients from Morocco, enterococci were the
causative microorganisms in 23% of patients.26 In accordance with
our results, enterococci were identiﬁed more frequently in older
subjects (p = 0.02), Streptococcus spp were found to be associated
with native valves, and CoNS were associated with intracardiac
prosthetic material in a study reported from Israel.20
Antimicrobial resistance was not a major problem among the
microorganisms isolated from community-acquired endocarditis,
but it was in healthcare-associated IE in our study: all of the
streptococci were sensitive to penicillin and all of the enterococci
were sensitive to penicillin, high-level gentamicin, and vancomy-
cin. Despite increasing reports of strains of viridans group
streptococci that are resistant to penicillin and other antibiotics,
penicillin-resistant viridans group streptococci are reported very
rarely as a cause of IE.27 No methicillin resistance was seen with S.
aureus strains isolated from community-acquired IE, but 25% of
healthcare-associated S. aureus IE strains were resistant to
methicillin in our study. Methicillin resistance rates among S.
aureus strains isolated from healthcare-associated IE cases
decreased signiﬁcantly from 45% to 8%, which was probably
related to the control of nosocomial MRSA infections in our
hospital after 2006. The rate of methicillin resistance among CoNS
strains isolated from 295 patients with IE in the present study was
S. S¸ ims¸ ek-Yavuz et al. / International Journal of Infectious Diseases 30 (2015) 106–114 113high in both community- (58%) and healthcare-associated (63%) IE.
In the study of Chu et al., the rate of methicillin resistance among
CoNS strains isolated from healthcare-associated IE was also very
high (58%), but the rate of methicillin resistance among CoNS
strains isolated from community-acquired IE was lower (22%) than
our results.28 The higher rate of methicillin resistance among CoNS
strains isolated from community-acquired IE cases in our study
may be a reﬂection of the higher rate of consumption of
antimicrobials in the community in Turkey.29 These results
suggest that penicillin or ampicillin and ampicillin–sulbactam or
cefazolin are still suitable antimicrobials for the treatment of
streptococcal or enterococcal and S. aureus IE in Turkey,
respectively. Because Gram-negative rods, especially non-fermen-
tatives, were the causative microorganisms in 38% and 27% of early
prosthetic valve IE cases in our study, we recommend that the
empirical therapy for these cases includes an antimicrobial
effective against these bacteria, which is compatible with the
current treatment guidelines.30
The mortality rate of our patients was very high (27.8%). Our
hospital is a referral centre for the surgical treatment of IE, thus this
higher mortality rate could be due to the referral of more
complicated cases. Because ﬁndings of progressive and uncon-
trolled infection such as heart failure or CNS emboli lead to higher
mortality in cases of IE, as found in our study and others,1,2 cases of
IE must be monitored closely and managed properly before such
complications occur.
Chronic haemodialysis was deﬁned as an independent risk
factor for mortality in our study, which is in accordance with the
current knowledge. Chronic haemodialysis patients are at higher
risk of IE with 50–180 times the incidence compared to the general
population.31 IE causes greater morbidity and mortality in dialysis
patients with infection, being second only to cardiovascular
disease as the leading cause of death within this patient group.
The mortality rate among dialysis patients with IE is at least twice
the mortality for IE in the general population and ranges from 30%
to 64%.31–33 Since an increased risk of IE results mainly from
vascular access-related bacteraemia, the prevention (preference of
native arteriovenous ﬁstula over an indwelling vascular catheter
for vascular access, nasal S. aureus decolonization of patients, etc.),
early detection, and effective treatment of bacteraemia among
chronic haemodialysis patients are very important because of the
unacceptably high mortality rate of IE among these patients.
The use of a surgical intervention was found to be a protective
factor against mortality in our study. Our study was not designed
to establish the impact of surgery on the mortality of patients with
IE. Although an inverse association was shown between valve
surgery and mortality, this does not show a cause–effect
relationship between surgery and mortality. Early surgical
intervention has been reported repeatedly as a protective factor
for mortality in recent studies.34–36 Although controversies exist,
the current literature indicates that valve surgery is associated
with signiﬁcantly reduced mortality in patients with left-sided IE,
therefore the management of complicated IE has moved into an era
of early surgery.37,38
In conclusion, IE occurred in relatively young patients in Turkey.
Brucella spp should be considered as a frequent cause of IE in
Turkey. We should ﬁrst consider streptococci as the causative
agents of IE in young patients (age <40 years), those with ARF or
congenital heart valve disease, and those with community-
acquired native valve IE. Staphylococci should be taken into
consideration ﬁrst in the case of pacemaker lead IE, when there are
high levels of creatinine, and in healthcare-associated IE.
Enterococci could be the most probable causative agents of IE
particularly in patients aged >50 years, those on dialysis, those
with late prosthetic valve IE, and in cases with perivalvular abscess.
Early diagnosis and treatment of IE before complications develop iscrucial because the mortality rate is high among cases of IE with
CNS emboli or CHF. The prevention of bacteraemia with available
measures among chronic haemodialysis patients should be a
priority because of the higher mortality rates of subsequent IE
observed in this group of patients.
Conﬂict of interest/funding: None.
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